Skip to main content
Premium Trial:

Request an Annual Quote

Progknowse, Premier Join With Three Health Systems on Predictive Analytics

NEW YORK – Progknowse, a developer of predictive analytics to support precision medicine, today announced partnerships with three East Coast health systems. Also participating is healthcare group purchasing alliance and services company Premier.

LifeBridge Health in Baltimore, Riverside Health System in Newport News, Virginia, and St. Luke's University Health Network in Bethlehem, Pennsylvania, have signed on to use the under-development Progknowse technology platform. McLean, Virginia-based Progknowse is creating technology to make actionable therapeutic recommendations to clinicians.

The company said that the technology will be compatible with Premier's PremierConnect performance improvement system. PremierConnect contains de-identified clinical outcomes data from about 45 percent of all patient discharges in the US, according to Charlotte, North Carolina-based Premier.

To power its predictive analytics, Progknowse is working with sequencing companies and health systems to build a clinical and genomic dataset. The startup did not provide a timetable for creating this dataset.

"Our partnership with Premier and these exemplary health systems enables clinician-driven data science collaboration that helps solve the problems of predictive accuracy and risk-adjustment crucial to improving the way care is delivered in precise and personalized ways," Progknowse Founder and CEO Marshall Ruffin said in a statement.

"We enjoy working with other like-minded regional health systems to build a platform for precision medicine that is both innovative and affordable," added Riverside Health System Chief Medical Informatics Officer Charles Frazier. "By applying these predictive algorithms to our health data, we hope to accurately predict patients' outcomes of a specific treatment to help patients, their families, and their clinicians select best treatments for them."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.